“ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER ”. 2022. World Bulletin of Public Health 12 (July): 66-69. https://scholarexpress.net/index.php/wbph/article/view/1135.